Literature DB >> 21406338

France: Health system review.

Karine Chevreul1, Isabelle Durand-Zaleski, Stéphane Bahrami Bahrami, Cristina Hernández-Quevedo, Philipa Mladovsky.   

Abstract

The Health Systems in Transition (HiT) profiles are country-based reports that provide a detailed description of a health system and of policy initiatives in progress or under development. HiTs examine different approaches to the organization, financing and delivery of health services and the role of the main actors in health systems; describe the institutional framework, process, content and implementation of health and health care policies; and highlight challenges and areas that require more in-depth analysis. The French health care system is a mix of public and private providers and insurers. Public insurance, financed by both employees and employer contributions and earmarked taxes, is compulsory and covers almost the whole population, while private insurance is of a complementary type and voluntary. Providers of outpatient care are largely private. Hospital beds are predominantly public or private non-profit-making. The French population enjoys good health and a high level of choice of providers. It is relatively satisfied with the health care system. However, as in many other countries, the rising cost of health care is of concern with regards to the objectives of the health care system. Many measures were or are being implemented in order to contain costs and increase efficiency. These include, for example, developing pay-for-performance for both hospitals and self-employed providers and increasing quality of professional practice; refining patient pathways; raising additional revenue for statutory health insurance (SHI); and increasing the role of voluntary health insurance (VHI). Meanwhile, socioeconomic disparities and geographic inequality in the density of health care professionals remain considerable challenges to providing a good level of equity in access to health care. Organizational changes at the regional level are important in attempting to tackle both equity and efficiency-related challenges. While the organizational structure of the system remained very stable until the mid 1990s, in the following decade many changes occurred and several new institutions were created. Concurrently, the respective power and involvement of the parliament, government, local authorities and SHI in the policy-making process have evolved. However, the Ministry of Health has retained substantial control over the health system, although ongoing reforms at both the regional and the national levels may challenge its traditional role. This edition of the French HiT was written concurrently with the vote and implementation of the 2009 Hospital, Patients, Health and Territories Act, which dramatically changed again the organizational structure and management of the health care system at the regional and local level. In order to ensure a comprehensive description and understanding of the system, the HiT, therefore, describes both the previous organization and the reorganization following the Act. However, the implementation process of the Act and its formal application was still a work in progress at the time of completing the French HiT. World Health Organization 2010, on behalf of the European Observatory on health systems and Policies.

Entities:  

Mesh:

Year:  2010        PMID: 21406338

Source DB:  PubMed          Journal:  Health Syst Transit        ISSN: 1817-6119


  22 in total

1.  Is there a statistical relationship between economic crises and changes in government health expenditure growth? an analysis of twenty-four European countries.

Authors:  Jonathan Cylus; Philipa Mladovsky; Martin McKee
Journal:  Health Serv Res       Date:  2012-06-07       Impact factor: 3.402

2.  The Relationship Between the Scope of Essential Health Benefits and Statutory Financing: An International Comparison Across Eight European Countries.

Authors:  Philip J van der Wees; Joost J G Wammes; Gert P Westert; Patrick P T Jeurissen
Journal:  Int J Health Policy Manag       Date:  2015-09-12

Review 3.  Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review.

Authors:  Bonny Parkinson; Catherine Sermet; Fiona Clement; Steffan Crausaz; Brian Godman; Sarah Garner; Moni Choudhury; Sallie-Anne Pearson; Rosalie Viney; Ruth Lopert; Adam G Elshaug
Journal:  Pharmacoeconomics       Date:  2015-09       Impact factor: 4.981

4.  Could co-payments on drugs help to make EU health care systems less open to political influence?

Authors:  Livio Garattini; Katelijne van de Vooren
Journal:  Eur J Health Econ       Date:  2013-10

5.  Use of an emergency department in Saint-Laurent du Maroni, French guiana: does being undocumented make a difference?

Authors:  Anne Jolivet; Emmanuelle Cadot; Olivier Angénieux; Sophie Florence; Sophie Lesieur; Jacques Lebas; Pierre Chauvin
Journal:  J Immigr Minor Health       Date:  2014-08

6.  Quality of diabetes follow-up care and hospital admissions.

Authors:  L F Andrade; T Rapp; C Sevilla-Dedieu
Journal:  Int J Health Econ Manag       Date:  2018-06

7.  Cholecystectomy and Diagnosis-Related Groups (DRGs): patient classification and hospital reimbursement in 11 European countries.

Authors:  Gerli Paat-Ahi; Ain Aaviksoo; Maria Swiderek
Journal:  Int J Health Policy Manag       Date:  2014-11-13

8.  International developments in revenues and incomes of general practitioners from 2000 to 2010.

Authors:  Madelon Kroneman; Pascal Meeus; Dionne Sofia Kringos; Wim Groot; Jouke van der Zee
Journal:  BMC Health Serv Res       Date:  2013-10-24       Impact factor: 2.655

9.  The role and uptake of private health insurance in different health care systems: are there lessons for developing countries?

Authors:  Isaac Ao Odeyemi; John Nixon
Journal:  Clinicoecon Outcomes Res       Date:  2013-03-05

Review 10.  The burden and treatment of diabetes in France.

Authors:  Karine Chevreul; Karen Berg Brigham; Clara Bouché
Journal:  Global Health       Date:  2014-02-20       Impact factor: 4.185

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.